Lates News

According to AI quick news, Donghai Securities released a research report on May 14, giving a buy rating to Yifeng Pharmacy (603939.SH). The rating reasons mainly include: 1) stable growth in performance, highlighting the company's refined management ability; 2) double-digit growth in franchise and distribution businesses, high-speed development of O2O business; 3) continuous improvement in gross profit margin, basically stable operating indicators; 4) steady expansion pace, continuous promotion of cost reduction and efficiency improvement; 5) strengthening the layout of prescription outflow and achieving diversified horizontal expansion of operations. (Daily Economic News)